Compare · MRNA vs VIGL
MRNA vs VIGL
Side-by-side comparison of Moderna Inc. (MRNA) and Vigil Neuroscience Inc. (VIGL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and VIGL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $18.89B, about 45.6x VIGL ($414.1M).
- Over the past year, MRNA is up 69.2% and VIGL is up 2.4% - MRNA leads by 66.8 points.
- MRNA has hit the wire 15 times in the past 4 weeks while VIGL has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 11 for VIGL).
- Company
- Moderna Inc.
- Vigil Neuroscience Inc.
- Price
- $47.60+0.41%
- $8.06+0.25%
- Market cap
- $18.89B
- $414.1M
- 1M return
- -1.99%
- +0.94%
- 1Y return
- +69.23%
- +2.41%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2022
- News (4w)
- 15
- 0
- Recent ratings
- 25
- 11
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Vigil Neuroscience Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
- President Hoge Stephen converted options into 9,282 shares and covered exercise/tax liability with 4,488 shares, increasing direct ownership by 0.32% to 1,483,848 units (SEC Form 4) to satisfy tax liability
- Moderna to Present at Upcoming Conference in June 2026
- Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting
- Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus
- Chief Financial Officer Mock James M converted options into 1,101 shares and covered exercise/tax liability with 533 shares, increasing direct ownership by 0.98% to 58,316 units (SEC Form 4) to satisfy tax liability
Latest VIGL
- SEC Form 15-12G filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- SEC Form EFFECT filed by Vigil Neuroscience Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Vigil Neuroscience Inc.
- Large owner Atlas Venture Fund Xii, L.P. returned 5,836,874 shares to the company (SEC Form 4)
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.
- SEC Form S-8 POS filed by Vigil Neuroscience Inc.